Injection 80mg, 120mg

Treatment of adult male patients with advanced hormonedependent prostate cancer - patients without spinal metastases.

Degarelix should be recommended/initiated by specialist services– AMBER0 recommendation.

Degarelix is recommended as an alternative to lutenising hormone releasing hormone agonists (LHRH) for treatment of adult male patients with advanced hormone-dependent prostate cancer without spinal metastases ONLY in the following circumstances:

where LHRH analogues or concomitant anti-androgens are contra-indicated.
in patients on androgen deprivation therapy who have a significant cardiac history/severe cardiac disease.
very significant, symptomatic metastatic disease, and locally advanced disease to shrink the metastases.
impending bladder outlet obstruction due to prostate cancer.

Degarelix for treating advanced hormone-dependent prostate cancer (NICE TA404).